Summary - Funding Rounds

Founding Date

2004

Total Funding

$355 m

Investors

In total, Alder BioPharmaceuticals had raised $355 m. Alder BioPharmaceuticals is a subsidiary of Lundbeck

Alder BioPharmaceuticals Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

Cost of goods sold

113.0k

R&D expense

33.4m69.6m132.8m252.9m239.1m

General and administrative expense

12.5m16.7m26.1m38.1m47.5m

Operating expense total

45.9m86.3m158.9m291.0m286.6m

EBIT

8.8m(86.3m)(157.9m)(291.0m)(286.6m)

Interest expense

104.0k859.0k1.8m2.8m9.6m

Interest income

44.0k702.0k2.0m2.5m8.9m

Investment income

(185.0k)(643.0k)(222.0k)

Pre tax profit

8.9m(85.5m)(156.1m)(288.2m)(296.2m)

Net Income

8.9m(85.5m)(156.3m)(288.9m)(296.4m)

Alder BioPharmaceuticals Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

46.8m206.5m116.2m76.9m87.9m

Accounts Receivable

113.0k113.0k

Prepaid Expenses

11.0m7.4m

Inventories

28.2m936.0k

Current Assets

60.7m322.2m393.2m287.3m419.8m

PP&E

1.2m2.0m7.1m5.6m6.4m

Total Assets

64.4m400.0m409.2m303.1m426.2m

Accounts Payable

1.9m4.7m10.4m7.5m8.9m

Current Liabilities

5.0m12.4m25.9m23.4m28.2m

Long-term debt

182.1m

Total Debt

182.1m

Total Liabilities

26.4m23.9m212.5m

Common Stock

7.0k7.0k

Additional Paid-in Capital

196.1m610.4m761.5m946.9m1.1b

Retained Earnings

(136.9m)(222.4m)(378.6m)(667.5m)(963.9m)

Total Equity

387.5m382.8m279.3m110.0m

Financial Leverage

1 x1.1 x1.1 x3.9 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

12.9m70.3m57.6m209.9m408.0m234.0m178.0m230.0m170.6m79.7m127.8m87.3m202.0m115.8m94.4m126.1m88.4m

Accounts Receivable

91.0k57.0k81.0k

Prepaid Expenses

1.3m4.1m7.1m11.3m13.7m13.6m16.6m15.8m23.7m19.8m21.2m17.6m7.3m7.6m6.6m3.8m11.0m

Inventories

936.0k936.0k936.0k936.0k936.0k

Current Assets

14.3m81.8m73.8m241.6m442.1m319.8m319.7m464.1m428.0m310.3m246.6m349.4m340.7m321.2m466.6m502.3m451.7m

PP&E

1.0m1.2m1.1m1.3m1.4m1.3m2.5m5.2m6.6m6.8m6.7m6.5m5.1m4.5m5.4m6.1m6.4m

Total Assets

16.6m85.6m75.8m242.9m443.5m426.3m372.4m474.4m443.6m317.8m254.0m366.3m599.4m548.4m496.8m513.2m462.6m

Accounts Payable

2.1m2.8m1.8m2.2m2.4m7.7m9.6m8.4m5.7m20.3m19.8m22.6m12.8m15.7m16.2m15.3m7.7m

Dividends Payable

1.1m1.3m1.3m

Current Liabilities

22.7m23.2m10.7m6.6m6.7m14.5m14.6m16.2m16.8m29.6m34.1m38.7m25.6m29.5m30.4m60.3m50.5m

Long-term debt

173.2m176.1m179.0m189.5m192.4m

Total Debt

173.2m176.1m179.0m189.5m192.4m

Total Liabilities

53.8m49.8m10.9m6.8m6.8m14.6m14.7m16.3m16.9m30.1m34.5m39.1m199.3m207.6m211.6m252.4m245.7m

Common Stock

1.0m3.0k3.0k4.0k4.0k4.0k4.0k5.0k5.0k5.0k5.0k7.0k7.0k7.0k7.0k8.0k8.0k

Additional Paid-in Capital

2.6m194.5m194.9m387.8m605.9m607.8m613.5m752.6m756.4m766.7m773.1m940.4m1.1b1.1b1.1b1.2b1.3b

Retained Earnings

(151.2m)(158.6m)(130.0m)(151.6m)(169.2m)(196.2m)(255.7m)(294.6m)(329.7m)(479.0m)(553.6m)(613.2m)(754.5m)(822.9m)(883.8m)(1.1b)(1.1b)

Total Equity

(148.6m)35.9m64.9m236.2m436.7m411.7m357.7m458.1m426.7m287.8m219.4m327.2m302.4m239.7m184.0m157.1m110.3m

Financial Leverage

-0.1 x2.4 x1.2 x1 x1 x1 x1 x1 x1 x1.1 x1.2 x1.1 x2 x2.3 x2.7 x3.3 x4.2 x

Alder BioPharmaceuticals Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

8.9m(85.5m)(156.3m)(288.9m)(296.4m)

Depreciation and Amortization

701.0k751.0k1.7m3.0m2.6m

Accounts Receivable

203.0k113.0k113.0k

Inventories

95.0k(936.0k)936.0k

Accounts Payable

(312.0k)2.8m5.5m(2.4m)1.3m

Cash From Operating Activities

(47.7m)(81.2m)(159.7m)(226.6m)(250.8m)

Purchases of PP&E

(649.0k)(1.2m)(6.6m)(2.0m)(3.1m)

Cash From Investing Activities

(9.7m)(167.3m)(67.7m)34.4m(121.1m)

Cash From Financing Activities

81.0m408.2m137.1m162.9m377.9m

Net Change in Cash

(29.3m)6.0m

Interest Paid

3.6m

Alder BioPharmaceuticals Ratios

USDQ1, 2014

Financial Leverage

-0.1 x

Alder BioPharmaceuticals Employee Rating

4.122 votes
Culture & Values
3.8
Work/Life Balance
4.1
Senior Management
3.6
Salary & Benefits
4.3
Career Opportunities
3.4
Source